vs
FIRST HORIZON CORP（FHN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FIRST HORIZON CORP的季度营收约是Revvity的1.2倍（$888.0M vs $772.1M），FIRST HORIZON CORP净利率更高（29.4% vs 12.7%，领先16.7%），FIRST HORIZON CORP同比增速更快（21.8% vs 5.9%），FIRST HORIZON CORP自由现金流更多（$389.0M vs $161.8M），过去两年FIRST HORIZON CORP的营收复合增速更高（20.0% vs 9.0%）
第一地平线公司（前身为第一田纳西银行）是一家成立于1864年的金融服务企业，总部位于美国田纳西州孟菲斯市。该公司通过旗下子公司第一地平线银行开展业务，网点覆盖美国东南部12个州，是该区域第四大区域性银行。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FHN vs RVTY — 直观对比
营收规模更大
FHN
是对方的1.2倍
$772.1M
营收增速更快
FHN
高出16.0%
5.9%
净利率更高
FHN
高出16.7%
12.7%
自由现金流更多
FHN
多$227.2M
$161.8M
两年增速更快
FHN
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $888.0M | $772.1M |
| 净利润 | $261.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 38.5% | 14.5% |
| 净利率 | 29.4% | 12.7% |
| 营收同比 | 21.8% | 5.9% |
| 净利润同比 | 57.2% | 3.9% |
| 每股收益（稀释后） | $0.51 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHNRVTY
| Q4 25 | $888.0M | $772.1M | ||
| Q3 25 | $889.0M | $698.9M | ||
| Q2 25 | $830.0M | $720.3M | ||
| Q1 25 | $812.0M | $664.8M | ||
| Q4 24 | $729.0M | $729.4M | ||
| Q3 24 | $827.0M | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | $819.0M | $649.9M |
净利润FHNRVTY
| Q4 25 | $261.0M | $98.4M | ||
| Q3 25 | $262.0M | $46.7M | ||
| Q2 25 | $241.0M | $53.9M | ||
| Q1 25 | $218.0M | $42.2M | ||
| Q4 24 | $166.0M | $94.6M | ||
| Q3 24 | $218.0M | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | $192.0M | $26.0M |
毛利率FHNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FHNRVTY
| Q4 25 | 38.5% | 14.5% | ||
| Q3 25 | 38.7% | 11.7% | ||
| Q2 25 | 37.2% | 12.6% | ||
| Q1 25 | 35.1% | 10.9% | ||
| Q4 24 | 28.8% | 16.3% | ||
| Q3 24 | 34.0% | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | 31.0% | 6.8% |
净利率FHNRVTY
| Q4 25 | 29.4% | 12.7% | ||
| Q3 25 | 29.5% | 6.7% | ||
| Q2 25 | 29.0% | 7.5% | ||
| Q1 25 | 26.8% | 6.4% | ||
| Q4 24 | 22.8% | 13.0% | ||
| Q3 24 | 26.4% | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | 23.4% | 4.0% |
每股收益（稀释后）FHNRVTY
| Q4 25 | $0.51 | $0.86 | ||
| Q3 25 | $0.50 | $0.40 | ||
| Q2 25 | $0.45 | $0.46 | ||
| Q1 25 | $0.41 | $0.35 | ||
| Q4 24 | $0.29 | $0.77 | ||
| Q3 24 | $0.40 | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | $0.33 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.8B | $7.3B |
| 总资产 | $83.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FHNRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益FHNRVTY
| Q4 25 | $8.8B | $7.3B | ||
| Q3 25 | $8.9B | $7.4B | ||
| Q2 25 | $9.0B | $7.6B | ||
| Q1 25 | $8.7B | $7.6B | ||
| Q4 24 | $8.8B | $7.7B | ||
| Q3 24 | $9.0B | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | $8.9B | $7.8B |
总资产FHNRVTY
| Q4 25 | $83.9B | $12.2B | ||
| Q3 25 | $83.2B | $12.1B | ||
| Q2 25 | $82.1B | $12.4B | ||
| Q1 25 | $81.5B | $12.4B | ||
| Q4 24 | $82.2B | $12.4B | ||
| Q3 24 | $82.6B | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | $81.8B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $396.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $389.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 43.8% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.52× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $595.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FHNRVTY
| Q4 25 | $396.0M | $182.0M | ||
| Q3 25 | $-200.0M | $138.5M | ||
| Q2 25 | $83.0M | $134.3M | ||
| Q1 25 | $349.0M | $128.2M | ||
| Q4 24 | $191.0M | $174.2M | ||
| Q3 24 | $389.0M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | $838.0M | $147.6M |
自由现金流FHNRVTY
| Q4 25 | $389.0M | $161.8M | ||
| Q3 25 | $-208.0M | $120.0M | ||
| Q2 25 | $74.0M | $115.5M | ||
| Q1 25 | $340.0M | $112.2M | ||
| Q4 24 | $174.0M | $149.8M | ||
| Q3 24 | $383.0M | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | $828.0M | $129.7M |
自由现金流率FHNRVTY
| Q4 25 | 43.8% | 21.0% | ||
| Q3 25 | -23.4% | 17.2% | ||
| Q2 25 | 8.9% | 16.0% | ||
| Q1 25 | 41.9% | 16.9% | ||
| Q4 24 | 23.9% | 20.5% | ||
| Q3 24 | 46.3% | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | 101.1% | 20.0% |
资本支出强度FHNRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 2.3% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | 1.2% | 2.7% |
现金转化率FHNRVTY
| Q4 25 | 1.52× | 1.85× | ||
| Q3 25 | -0.76× | 2.97× | ||
| Q2 25 | 0.34× | 2.49× | ||
| Q1 25 | 1.60× | 3.03× | ||
| Q4 24 | 1.15× | 1.84× | ||
| Q3 24 | 1.78× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 4.36× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FHN
| Commercial Consumer And Wealth Segment | $776.0M | 87% |
| Other | $88.0M | 10% |
| Corporate | $24.0M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
